Slowing or Delaying Vision Loss in Retinitis Pigmentosa (USH2A gene mutation subtype) → Hypothesis
Pharmacological Treatments Can Slow Degeneration
exploringStrength Assessment
neutralWhat Would Help
- - More supporting evidence needed
- - More contributions that test or support this hypothesis
- - Link or collect evidence to ground this hypothesis
AI AI Analysis
AI will summarize findings, assess strength, identify gaps, and suggest next steps.
Summary
Mixed evidence. Some historical support for Vitamin A but with safety concerns. Neuroprotective agents are early-stage.
Edit summary
Description
Other Hypotheses
Key Findings
Potential benefit is uncertain and may depend on dosage and patient profile. Risk-benefit balance is unclear, especially for USH2A-specific RP.
Next Step Suggestion: Investigate whether USH2A-specific studies exist for Vitamin A. Review current ophthalmologist recommendations.
Evidence (0)
No evidence linked yet.
Link existing evidence or collect new evidence to support this hypothesis.
Link evidence to this hypothesis
Related Open Questions
🎯 If you had to decide today
Based on this hypothesis: What would you do? What would you ignore? What evidence is still missing?
Did this help you?
User-reported outcomes, not medical advice.
Contributions (1)
+ Add ContributionDoes Vitamin A slow RP progression?
Literature review of historical clinical recommendations and meta-analyses on Vitamin A palmitate fo...
Mixed evidence. The original Berson trial suggested ~20% slower decline in ERG amplitude with 15,000...